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Working Together in a Challenging Environment:   
The Jefferson Industry Advisory Council (JIAC) 
__________________________________________ 
 
Under the leadership of Dr. Geno Merli, the Ludwig Kind Professor of 
Medicine and former Senior Associate Dean for CME, Dr. Richard Wender, 
the Alumni Professor and Chairman of the Department of Family Medicine 
and Chairman of the Jefferson Medical College CME Committee, and Dr. 
David Nash, the Dr. Raymond C. and Doris N. Grandon Professor of Health 
Policy and Chairman of the Department of Health Policy, the Jefferson 
Industry Advisory Council (JIAC) serves as a forum in which representatives 
from across the Thomas Jefferson University can meet with representatives 
from pharmaceutical, biotechnical and other sectors of the healthcare 
industry to explore opportunities for partnering more effectively in 
recognition of current environmental constraints. 
A capacity crowd filled DiPalma auditorium for a special session of the Jefferson 
Industry Advisory Council, presented jointly by the Department of Health Policy and 
the Office of Continuing Medical Education on November 22, 2004. The topic, 
“Working Together in a Challenging Environment,” represented the continuation of 
an ongoing conversation about defining and negotiating relationships between 
academia and the pharmaceutical industry – an issue recognized as one of the most 
pressing in health care today. 
 
The first of two invited speakers was Dr. Arnold S. Relman whom Dr. Nash 
introduced as a true “Renaissance man” in the medical arena with impressive 
credentials as a physician, teacher, and researcher, former editor of the New England 
Journal of Medicine, and thought leader at the national level. Dr. Relman provoked 
and challenged the audience with his views on the separation of pharmaceutical 
marketing from medical education. He began by drawing distinctions between 
medicine and the pharmaceutical industry in terms of focus (“a serving profession 
without fiduciary responsibility versus a product-centered industry with primary 
responsibility to investors”) and educational approach (educating its own using 
evidence-based knowledge that is independent of the Market versus marketing and 
informing”). Noting the public’s reliance on medical education that is focused on the 
best and safest way to diagnose and treat a condition without regard for 
marketability, he contended that collaboration between academic educators and the 
pharmaceutical industry represents “an inherent conflict of interest.” In the area of 
research, Dr. Relman spoke in favor of collaboration on well-regulated activities. He 
appraised the American College of Graduate Medical Education (ACGME) guidelines 
as inadequate because they are not enforceable. Rather than each medical institution 
developing its own guidelines, he advised that the American Association of Medical 
Colleges (AAMC) be persuaded to convene a public meeting of the major medical 
schools to develop set of policies all can subscribe to. 
 
Citing statistics generated by the Securities and Exchange Commission (SEC), Dr. 
Relman reasoned that the huge amounts spent by pharmaceutical companies on 
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continuing medical education (CME) inevitably and unavoidably influence topics and 
content. “This sets a bad precedent for fledgling physicians, undermines professional 
self-respect, weakens public trust in the profession, and increases drug 
costs – employers and patients are paying for it in the final analysis.” 
 
Currently, 60-70 percent of the cost of CME is borne by the pharmaceutical industry. 
What do we do without industry support?  Dr. Relman’s proposed solution included 
more modest meetings (“The biggest names are not necessarily the best teachers.”), 
greater use of full-time faculty by providers, more efficient pedagogic methods, and 
increases in student tuition. 
 
The second speaker, James G. Sheehan JD (Associate U.S. Attorney and Chief of the 
Civil Division, US Department of Justice), spoke on “Current Enforcement Issues in 
Health Care Fraud”. Among the three general areas (research fraud, corporate 
governance/quality and errors, and “dead patients”), he noted that most collusion is 
found in financial coding and payment. Citing historical examples, he pointed 
out that research fraud is neither a recent phenomenon nor is it motivated by pure 
greed. Falsification, overstatement or misreporting data, and misrepresenting 
credentials are the most common events. 
 
How does the financial conflict-of-interest component of research affect the 
credibility of the science? Some studies suggest that 40 percent of researchers are 
aware of financial misconduct but have not reported it, in large part because of a 
belief that the ends (i.e., getting funding for the next important grant) justifies the 
means (i.e., misreporting). He stressed the importance of effective organizational 
compliance plans to minimize the risk of fraud. 
 
